Faruqi & Faruqi, LLP is investigating the claims on behalf of Humacyte By Investing.com investors

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson encourages investors who have suffered losses greater than $75,000 in Humacyte to contact him directly to discuss their options

If you have suffered losses greater than $75,000 Humacytes between May 10, 2024 and October 17, 2024 and want to discuss your legal rights, call a Faruqi & Faruqi partner Josh Wilson direct on 877-247-4292 or 212-983-9330 (ext. 1310).

[You may also click here for additional information]

New York, New York–(Newsfile Corp. – December 28, 2024) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Humacyta, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA ) and reminds investors of The deadline is January 17, 2025 to seek the role of lead plaintiff in a federal securities class action brought against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The company has recovered hundreds of millions of dollars for investors since its inception in 1995. See www.faruqilaw.com.

As set forth below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the following: (1) that the Company’s facility in Durham, North Carolina, did not adhere to good manufacturing practices, including quality assurance and microbial testing; (2) that the FDA’s review of the BLA will be delayed until Humacyte corrects these deficiencies; and (3) that, as a result, there was a significant risk to FDA approval of ATEV for vascular trauma; and (4) that, as a result of the above, the defendant’s positive statements about the Company’s business, operations and prospects were materially misleading and/or lacked a reasonable basis.

On August 9, 2024, after the market closed, Humacyte issued a press release announcing that the Food and Drug Administration (“FDA”) “will need additional time to complete its review of its Biologics License Application ( BLA) for acellular tissue engineering of a vessel (ATEV) in the indication of vascular trauma.” The press release revealed in part that, “[d]during BLA review, the FDA conducted inspections of our manufacturing facilities and clinical sites and actively engaged with us in numerous discussions related to our BLA submission[.]”

Following this news, the Company’s share price fell $1.29, or 16.4%, to $6.62 per share on August 12, 2024, due to unusually high volume.

On October 17, 2024, during market hours, the FDA released a Form 483 related to Humacyte’s facility in Durham, North Carolina, which disclosed a number of violations, including “no microbial quality assurance,” “no microbial testing,” and inadequate “quality control”. .”

Following this news, the Company’s share price fell $0.95, or 16.35%, to $4.86 per share on October 17, 2024, due to unusually high volume.

A court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who is adequate and typical of the class members and who directs and oversees the litigation on behalf of the putative class. Any putative class member may propose to the Court to serve as lead plaintiff through counsel of his or her choosing, or may choose to do nothing and remain an absent class member. Your ability to participate in any recovery is not affected by the decision whether or not you will be the lead plaintiff.

Faruqi & Faruqi, LLP also encourages anyone with information about Humacyte’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.

Follow us for updates on LinkedIn, on X or on Facebook (NASDAQ:).

Advertising of lawyers. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your specific case. All communications will be treated confidentially.

To view the original version of this press release, visit https://www.newsfilecorp.com/release/234707